Clinical Context GLP-1 receptor agonists produce substantial weight loss, but the mechanisms underlying this effect have been debated. Is weight…
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
Clinical Context Heart failure with preserved ejection fraction (HFpEF) represents one of the most challenging conditions in cardiovascular medicine. Unlike…
A small randomised trial finding that weight loss reduced IL-1β and MASLD comparably with liraglutide or lifestyle, and that baseline IL-1β predicted the extent of MASLD improvement. PICO summary and expert commentary.
An exploratory secondary analysis of two Phase 2 trials reports that oral orforglipron lowered blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP versus placebo, though no cardiovascular events were measured. PICO summary and expert commentary.
A multicentre randomised trial found dapagliflozin 10 mg daily for 48 weeks improved biopsy-confirmed MASH without worsening fibrosis in more patients than placebo. PICO summary and expert commentary.
A single-centre, open-label randomised trial of empagliflozin 10 mg in 70 patients with type 2 diabetes and HFpEF found improved 6-minute walk distance and diastolic reserve markers. PICO summary and expert commentary.
Design paper for the DAPA ACT HF-TIMI 68 trial testing in-hospital dapagliflozin versus placebo in 2,401 patients with acute heart failure; no efficacy results are reported. PICO summary and expert commentary.
A biomarker substudy of the EMPEROR program shows empagliflozin activates the erythropoietin-erythroferrone-hepcidin axis and raises haemoglobin in heart failure. PICO summary and expert commentary.
A 24-week open-label randomised trial testing pioglitazone plus empagliflozin versus monotherapy for fatty liver in type 2 diabetes. PICO summary and expert commentary.
The PARTNER study is a published trial protocol, not a results paper: it describes the rationale and design of a randomised crossover trial of dapagliflozin plus continuous ketone monitoring in type 1 diabetes, with no outcomes yet reported. PICO summary and expert commentary.